Western blot analysis of extracts from 293 cells, untreated (-) or treated with Calyculin A #9902 (50 nM, 1 hr; +) with or without pretreating the cells with CHIR-99021 (10 μM, 1 hr; +), using Phospho-c-Myc (Thr58) (E4Z2K) Rabbit mAb #46650 (upper), c-Myc (E5Q6W) Rabbit mAb #18583 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of CHIR-99021.
CHIR-99021 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.07 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|MW (kDa)||465.3 g/mol|
|Solubility||Soluble in DMSO at 25 mg/ml with slight warming.|
CHIR-99021, also known as CT-99021, is a potent and selective inhibitor of glycogen synthase kinase-3β (GSK-3β) and GSK-3α with IC50 values of 6.7 and 10 nM, respectively. This small compound has been shown to have >500-fold selectivity for GSK-3 when tested against 20 different protein kinases (1). Studies have shown that treating isolated rat islets with CHIR-99021 can increase beta cell replication 2-3-fold, making this an important compound when studying type 1 and type 2 diabetes (2).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.